11:07 AM
 | 
May 15, 2018
 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD)

Patient sample and mouse experiments suggest that inhibiting CEBPB could help treat AD. In postmortem brain tissue samples from patients, levels of CEBPB were higher than in samples from unaffected subjects. In two...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >